Study first to confirm effectiveness and safety of new treatment for hemophilia
Wednesday, November 2, 2011 - 16:30
in Health & Medicine
An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place. The study, the first to confirm the efficacy and safety of the drug FEIBA in bleed prevention is published in the Nov. 3, 2011 issue of the New England Journal of Medicine.
